PharmaCyte Biotech, Inc.

PMCB Nasdaq SEC CIK 1157075
Follow PharmaCyte Biotech Weekly email: filings, results

Financials

Reported figures only · latest: Q1 2027 USD · US GAAP
Revenue, last quarter $0
Net income −$5.1M +39.2% vs same quarter last year
EPS, diluted −$0.54 +56.1% vs same quarter last year
Operating cash flow −$780.9K +60.8% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$40M−$20M$0$20M$40MFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26$0−$19.4M
FY25$0$30.7M
FY24$0$333.8K
FY23$0−$4.3M
FY22$0−$4.2M
FY21$0−$3.6M
FY20$0−$3.8M
FY19$0−$4.1M
FY18$0−$6.8M
FY17$0−$4.4M
FY16$0−$6.1M
FY15$0−$9.9M
FY14$0−$27.3M
FY13$12.2K−$1.6M
FY12$66.6K−$1.9M
Returned to shareholdersDividends paid and shares bought back
$0$10M$20M$30MFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearBuybacks
FY26$401.6K
FY25$2.5M
FY24$28.2M
FY23$13.6M
FY22$0
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-